Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
about
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesionsSystemic treatments for metastatic cutaneous melanomaDistinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signallingSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibImproved survival with vemurafenib in melanoma with BRAF V600E mutationPhytochemicals for the Management of MelanomaChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Melanoma: oncogenic drivers and the immune systemThe influence of subclonal resistance mutations on targeted cancer therapyTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Managing Side Effects of Vemurafenib Therapy for Advanced MelanomaMelanoma brain metastases: an unmet challenge in the era of active therapyBeyond BRAF: where next for melanoma therapy?New treatments for metastatic melanomaTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondNRAS mutation status is an independent prognostic factor in metastatic melanoma.Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapyTERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in MelanomaLong Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation.Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in MelanomaImmunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastasesExpression of drug targets in patients treated with sorafenib, carboplatin and paclitaxelBRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsAlcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer CellsRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsFunction and Clinical Implications of Long Non-Coding RNAs in Melanoma.BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications.Melanoma brain metastases: correlation of imaging features with genomic markers and patient survival.Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study.PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.Melanoma epidemiology, biology and prognosis.Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialCorrelation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibMolecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.
P2860
Q21004109-3CFE61FA-120D-45FE-AF96-C5D811A361B2Q24194804-275695AD-646C-4361-951D-25BF4F4195BEQ24314807-A8CDEE11-9CDF-483D-A67A-71D85CF04693Q24594790-4B7A12B9-F83F-4FF6-8224-2A8AFE255D73Q24631953-B7839D4D-273C-4C26-A175-20FBB6AC2370Q26766708-EC5C57ED-520A-46F9-B72A-C96FF43FEA29Q26770492-EC16386C-6AC5-4640-A1F1-9611CA2A67D3Q26775598-32FD34D8-AB90-4859-96F1-C110AEC8A33DQ26781693-414580AB-8B4B-46C3-BA50-37B7E7F40655Q26782222-8BE50B95-653E-4BB6-B626-1477834D1412Q26795510-98358F58-5D67-4DE6-B7A8-FAE6C58F5C41Q26995622-E653D85E-6CF2-44B5-8E9D-A0B5F8020FA5Q27006853-FD33DA1F-F116-483E-A1AF-47F58BCEC009Q27007068-AF913494-0103-44E8-87AE-1821085519C9Q27026323-CE147FE1-204C-4C5E-8365-324B2B603222Q27851695-8BAD26AC-1FEF-4348-8E66-A8D9FB5F12DEQ27851801-F7E19F03-4140-46B5-B02C-2505D956CF7CQ27852389-E6401421-A197-41E3-8A42-FD0BB9DF87C4Q27852814-C388B61F-034F-4B42-A8D7-2B259CFA65E2Q27852927-C6214DCB-245F-461D-ACDF-0D2AF9A1CAECQ27853068-B3A7D028-06B0-4052-9F11-9952A9BCB306Q27853202-92E270F1-1275-41D6-9E7A-630678381613Q27853361-D6F06CFD-4728-4614-9999-CE97B613C85FQ28069018-1C99E7B5-5202-4C69-9FBB-636633589E48Q28250795-C03B1833-0608-47B9-B58C-AA7D67A48EB3Q28535159-E5E8A0BE-F5A3-4CD4-BA11-4FE104E2DD83Q28543370-3AFEBFBA-F6D1-492A-A308-9B99C6ABC5C8Q28551506-A7056049-7C73-4616-A6C7-E5DC8DA85F73Q28730438-9DBE8786-02CC-4825-B176-2F85884CE6E9Q30313298-8E1FB58D-7D79-4B7F-8CB5-4C7A71ABB551Q30458424-1A0D2F51-6776-43E0-85B1-4FF612E0B456Q30828178-A84C4FED-900A-4521-A4C8-63E2E34F8FCEQ31010216-34CAC08F-5DDF-4E16-AE92-2722023F3B40Q31141368-E41D7D01-172D-474D-80D0-36ACE55FEAFEQ33682137-2F0B87F4-5655-4481-AF5B-4B507DC5FD3DQ33688428-7B9C6D21-A59A-46E6-899E-DFB7F11FAAB6Q33698718-FEF35ABA-5F79-484B-8CE4-E979AFE05952Q33749057-E6E21329-3E3D-461F-AD3C-E34E6912862EQ33758211-09F22D9A-080A-43F5-8BE9-E31B8E67B95AQ33778554-7C26EDF4-B06D-4B35-A073-4A863F75A652
P2860
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
@en
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
@nl
type
label
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
@en
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
@nl
prefLabel
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
@en
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
@nl
P2093
P50
P356
P1476
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
@en
P2093
Adnan M Nagrial
Anne L Hamilton
John F Thompson
Lauren E Haydu
P304
P356
10.1200/JCO.2010.32.4327
P407
P577
2011-02-22T00:00:00Z